UniProtKB/Swiss-Prot Q8N2S1: Variant p.Thr1141Met

Latent-transforming growth factor beta-binding protein 4
Gene: LTBP4
Feedback?

Variant information Variant position:

1141 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Threonine (T) to Methionine (M) at position 1141 (T1141M, p.Thr1141Met). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and polar (T) to medium size and hydrophobic (M) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

-1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Other resources:

Links to websites of interest for the variant.

Variant rs10880 [ dbSNP | Ensembl ]

Sequence information Variant position:

1141 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

1624 The length of the canonical sequence.
Location on the sequence:

SPEEFDPMTGRCVPPRTSAG T FPGSQPQAPASPVLPARPPP The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         SPEEFDPMTGRCVPPRTSAGTFPGSQPQAPASPVLPARPPP

Mouse                         SPEEFDPMTGRCVPPRAPAGTFPGSQPQAPASPSLPARPPA

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	28 – 1624	Latent-transforming growth factor beta-binding protein 4
Region	1130 – 1179	Disordered

Literature citations
Sequence and expression of a novel member (LTBP-4) of the family of latent transforming growth factor-beta binding proteins.
Giltay R.; Kostka G.; Timpl R.;
FEBS Lett. 411:164-168(1997)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3); TISSUE SPECIFICITY; VARIANT MET-1141; Identification and characterization of a new latent transforming growth factor-beta-binding protein, LTBP-4.
Saharinen J.; Taipale J.; Monni O.; Keski-Oja J.;
J. Biol. Chem. 273:18459-18469(1998)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2); SUBCELLULAR LOCATION; ALTERNATIVE SPLICING; TISSUE SPECIFICITY; DEVELOPMENTAL STAGE; INTERACTION WITH LTBP1 AND TGFB1; VARIANTS ILE-194; ALA-787; ALA-820 AND MET-1141; LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy.
Flanigan K.M.; Ceco E.; Lamar K.M.; Kaminoh Y.; Dunn D.M.; Mendell J.R.; King W.M.; Pestronk A.; Florence J.M.; Mathews K.D.; Finkel R.S.; Swoboda K.J.; Gappmaier E.; Howard M.T.; Day J.W.; McDonald C.; McNally E.M.; Weiss R.B.;
Ann. Neurol. 73:481-488(2013)
Cited for: VARIANTS ILE-194; ALA-787; ALA-820 AND MET-1141; INVOLVEMENT IN DMD; Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History Study.
Bello L.; Kesari A.; Gordish-Dressman H.; Cnaan A.; Morgenroth L.P.; Punetha J.; Duong T.; Henricson E.K.; Pegoraro E.; McDonald C.M.; Hoffman E.P.;
Ann. Neurol. 77:684-696(2015)
Cited for: VARIANT MET-1141; INVOLVEMENT IN DMD;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.